Drug
Faldaprevir clinical trials
Also written BI 201335.
Includes 6 studies of Faldaprevir sodium.
- studies test it
- 40
- open now
- 0
- in phase 3
- 9
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
40 studies that test it; most in 2012 (11)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 7 |
| 2012 | 11 |
| 2013 | 8 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 26
- Phase 2
- 5
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 0
Boehringer Ingelheim (39) · Trek Therapeutics, PBC (1)
Often tested with
Tested in the same studies.
Ribavirin (9) · Deleobuvir (9) · Peginterferon alfa-2a (3) · Midazolam (2) · Tenofovir (2) · Tolbutamide (2) · Deleobuvir sodium (2) · TD-6450 (1)
Studies
Open first, then newest update. How each study uses faldaprevir is read from its arms, and is right about nine times in ten.
Testing it · 40
- Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -ExperiencedCompletedPhase 1Boehringer IngelheimNCT00793793Written as BI201335
- A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedPhase 2Trek Therapeutics, PBCNCT02593162Written as Faldaprevir
- Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedPhase 3Boehringer IngelheimNCT01399619Written as BI201335
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedPhase 3Boehringer IngelheimNCT01358864Written as BI 201335
- A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedPhase 3Boehringer IngelheimNCT01330316Written as BI 201335
- Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedPhase 1Boehringer IngelheimNCT01525628Written as BI 201335
- Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or TacrolimusCompletedPhase 1Boehringer IngelheimNCT02016625Written as Faldaprevir
- IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1CompletedPhase 3Boehringer IngelheimNCT01732796Written as BI 201335 (Faldaprevir)
- Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.CompletedPhase 1Boehringer IngelheimNCT01965431Written as Faldaprevir
- This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedPhase 2Boehringer IngelheimNCT01528735Written as BI 201335 NA
- Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired PatientsTerminatedPhase 1Boehringer IngelheimNCT01957657Written as faldaprevir
- Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and LevonorgestrelTerminatedPhase 1Boehringer IngelheimNCT01941615Written as faldaprevir
- Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsCompletedPhase 1Boehringer IngelheimNCT01737996Written as BI 207127 + faldaprevir
- Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2CompletedPhase 3Boehringer IngelheimNCT01728324Written as Faldaprevir: 24-week treatment
- Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedPhase 2Boehringer IngelheimNCT01132313Written as BI 201335
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedPhase 3Boehringer IngelheimNCT01297270Written as BI201335
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedPhase 3Boehringer IngelheimNCT01343888Written as BI 201335
- Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)CompletedPhase 2Boehringer IngelheimNCT00984620Written as BI 201335
- Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver CirrhosisCompletedPhase 1Boehringer IngelheimNCT01909778Written as BI 201335
- Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination TrialCompletedPhase 3Boehringer IngelheimNCT01579474Written as BI 201335 high dose
See all 40 studies that test faldaprevir →
Given in every arm · 7 — faldaprevir is usual care beside what is tested
- A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionCompletedPhase 2Trek Therapeutics, PBCNCT02716428Written as Faldaprevir
- Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CCompletedPhase 2Presidio Pharmaceuticals, Inc.NCT01859962Written as Faldaprevir
- BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3CompletedPhase 2Boehringer IngelheimNCT01830127Written as Faldaprevir
- Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)CompletedPhase 2Boehringer IngelheimNCT00774397Written as BI 201335 NA 240 mg QD / LI
- Investigation of Food Effect and Gastric ph Increase on the Bioavailability of FaldapravirCompletedPhase 1Boehringer IngelheimNCT01694706Written as faldaprevir
- Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02182375Written as BI 201335 NA
- Open Label Trial to Compare BI 207127 to Telaprevir in HCV PatientsWithdrawnPhase 3Boehringer IngelheimNCT01858961Written as BI 201335
Codes
What other systems call faldaprevir · ClinicalTrials.gg INT005710
- MeSH (NLM) C552340faldaprevirOne source NLM
- UNII (FDA) 958X4J301AFALDAPREVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q15408404faldaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171746FaldaprevirOne source FDA
- DrugBank DB11808One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552340 | faldaprevir | One source NLM |
| UNII (FDA) | 958X4J301A | FALDAPREVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15408404 | faldaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171746 | Faldaprevir | One source FDA |
| DrugBank | DB11808 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.